Zhejiang Huahai Pharmaceutical's holding subsidiary Hua Ao Tai plans to increase capital and expand shares and introduce the investor Haijing Venture Capital.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that, in line with the company's overall development plan, to further accelerate the implementation of the company's bio-innovative drug strategic layout, enhance the company's core competitiveness and sustainable development capabilities, and strengthen the operational capabilities of its holding subsidiary Hangzhou Alltest Biotech Pharmaceutical Co., Ltd. (referred to as "Huao Tai"), the company plans to introduce an investor, Linhai Haijing Entrepreneurial Investment Partnership Enterprise (Limited Partnership) (referred to as "Haijing Venture Capital"), to subscribe for 20 million newly issued shares of Huao Tai. After this capital increase and expansion, Huao Tai's registered capital will increase from 300 million RMB to 320 million RMB, and the total number of shares will increase from 300 million to 320 million.